Review of the validated HPLC and LC-MS/MS methods for determination of drugs used in clinical practice for Alzheimer's disease

2014 ◽  
Vol 28 (11) ◽  
pp. 1431-1490 ◽  
Author(s):  
Suresh Ponnayyan Sulochana ◽  
Kuldeep Sharma ◽  
Ramesh Mullangi ◽  
Sathesh Kumar Sukumaran
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Clinical Practice

scholarly journals Motor-Skill Learning in Alzheimer’s Disease: A Review with an Eye to the Clinical Practice

2007 ◽  
Vol 17 (3) ◽  
pp. 203-212 ◽  
Author(s):  
Ilse A. D. A. van Halteren-van Tilborg ◽  
Erik J. A. Scherder ◽  
Wouter Hulstijn
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Clinical Practice ◽  
Motor Skill ◽  
Skill Learning ◽  
Motor Skill Learning

A ratiometric electrochemical strategy for sensitive determination of Furin activity based on dual signal amplification and antifouling nanosurfaces

The Analyst ◽  
2017 ◽  
Vol 142 (22) ◽  
pp. 4215-4220 ◽  
Author(s):  
Dazhi Yao ◽  
Wenqi Zhao ◽  
Limin Zhang ◽  
Yang Tian
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Cell Surface ◽  
Signal Amplification ◽  
Accurate Method ◽  
Sensitive Determination ◽  
Dual Signal Amplification

Developing a sensitive and accurate method for Furin activity is still the bottleneck for understanding the role played by Furin in cell-surface systems and even in Alzheimer's disease.

Automatic determination of white matter hyperintensity properties in relation to the development of Alzheimer's disease

2016 ◽  
Author(s):  
Sandra van der Velden ◽  
Christoph Moenninghoff ◽  
Isabel Wanke ◽  
Martha Jokisch ◽  
Christian Weimar ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
White Matter ◽  
White Matter Hyperintensity ◽  
Automatic Determination

Planimetry of the medial temporal lobe: a feasible method for supporting the diagnosis of Alzheimer’s disease in clinical practice

10.3823/355 ◽  
2015 ◽  
Author(s):  
Manuel Menéndez González ◽  
Aníbal Fernández Oliveira ◽  
Francisco Conejo Bayón ◽  
Jesús Maese ◽  
Tamara Mesas Uzal ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Clinical Practice ◽  
Temporal Lobe ◽  
Medial Temporal Lobe ◽  
Feasible Method

Cognitive Assessment of Alzheimer’s Disease and Dementias in Clinical Practice

2019 ◽  
Vol 80 (4) ◽  
Author(s):  
Lynn Shaughnessy ◽  
Simon Sheard ◽  
Danielle Goldfarb ◽  
Alireza Atri
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Clinical Practice ◽  
Cognitive Assessment

Simulating the Effects of Common Comedications and Genotypes on Alzheimer’s Cognitive Trajectory Using a Quantitative Systems Pharmacology Approach

2020 ◽  
Vol 78 (1) ◽  
pp. 413-424
Author(s):  
Hugo Geerts ◽  
Athan Spiros
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Clinical Trials ◽  
Clinical Practice ◽  
Second Generation ◽  
Standard Of Care ◽  
Systems Pharmacology ◽  
Quantitative Systems Pharmacology ◽  
Pharmacodynamic Interactions ◽  
Cognitive Trajectory

Background: Many Alzheimer’s disease patients in clinical practice are on polypharmacy for treatment of comorbidities. Objective: While pharmacokinetic interactions between drugs have been relatively well established with corresponding treatment guidelines, many medications and common genotype variants also affect central brain circuits involved in cognitive trajectory, leading to complex pharmacodynamic interactions and a large variability in clinical trials. Methods: We applied a mechanism-based and ADAS-Cog calibrated Quantitative Systems Pharmacology biophysical model of neuronal circuits relevant for cognition in Alzheimer’s disease, to standard-of-care cholinergic therapy with COMTVal158Met, 5-HTTLPR rs25531, and APOE genotypes and with benzodiazepines, antidepressants, and antipsychotics, all together 9,585 combinations. Results: The model predicts a variability of up to 14 points on ADAS-Cog at baseline (COMTVV 5-HTTLPRss APOE 4/4 combination is worst) and a four-fold range for the rate of progression. The progression rate is inversely proportional to baseline ADAS-Cog. Antidepressants, benzodiazepines, first-generation more than second generation, and most antipsychotics with the exception of aripiprazole worsen the outcome when added to standard-of-care in mild cases. Low dose second-generation benzodiazepines revert the negative effects of risperidone and olanzapine, but only in mild stages. Non APOE4 carriers with a COMTMM and 5HTTLPRLL are predicted to have the best cognitive performance at baseline but deteriorate somewhat faster over time. However, this effect is significantly modulated by comedications. Conclusion: Once these simulations are validated, the platform can in principle provide optimal treatment guidance in clinical practice at an individual patient level, identify negative pharmacodynamic interactions with novel targets and address protocol amendments in clinical trials.

[P2-288]: VALIDATION OF THE NOVEL DEMENTIA ASSESSMENT SCALE FOR ALZHEIMER's DISEASE: A THREE-DIMENSIONAL SCORING ALGORITHM RELEVANT FOR CLINICAL PRACTICE

2017 ◽  
Vol 13 (7S_Part_15) ◽  
pp. P725-P726
Author(s):  
Takashi Kikuchi ◽  
Takahiro Mori ◽  
Shinsuke Kojima ◽  
Kenji Wada Isoe ◽  
Yumi Umeda Kameyama ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Clinical Practice ◽  
Three Dimensional ◽  
Assessment Scale ◽  
The Novel ◽  
Scoring Algorithm

UPLC-MS/MS method for determination of schisandrin in rat plasma and brain microdialysates: application to a comparative pharmacokinetic and brain distribution study in normal and Alzheimer’s disease rats

2017 ◽  
Vol 9 (32) ◽  
pp. 4740-4746 ◽  
Author(s):  
BinBin Wei ◽  
Mingyan Liu ◽  
Zaixing Chen ◽  
Minjie Wei
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Rat Plasma ◽  
Brain Distribution ◽  
Comparative Pharmacokinetic ◽  
Distribution Study

An efficient UPLC-MS/MS method for determining schisandrin in rat plasma and brain microdialysates has been developed and validated.

Sign in / Sign up

Export Citation Format

Share Document